Lupin debuts in Dow Jones best-in-class indices for ESG performance

Lupin debuts in Dow Jones best-in-class indices for ESG performance

By: IPP Bureau

Last updated : May 19, 2026 1:34 pm



The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index


Lupin Limited announced its first-time inclusion in the Dow Jones Best-in-Class (DJBIC) Indices, highlighting the company’s growing focus on sustainable, responsible, and ethical business practices.

The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index. The DJBIC World Index recognises companies globally for strong Environmental, Social, and Governance (ESG) performance, while the Emerging Markets Index highlights sustainability leaders across developing economies.

Earlier this year, Lupin Limited was also ranked among the top 1 percent globally in the S&P Global Corporate Sustainability Assessment (CSA) 2025, securing an industry-leading score of 91 out of 100.

The Dow Jones Best-in-Class Indices recognise organisations demonstrating exceptional performance across critical ESG parameters based on S&P Global CSA scores. Lupin stated that its inclusion reinforces the company’s credibility among global investors and strengthens its position among leading sustainability-focused companies worldwide.

Ramesh Swaminathan, Executive Director, Global CFO, Head of IT and API Plus SBU at Lupin Limited, said, “Lupin’s inclusion in the Dow Jones Best-in-Class Indices reflects the strength of our governance framework and financial discipline and marks a meaningful advancement in our sustainability journey. This recognition reinforces our long-term value creation agenda—anchored in responsible growth, resilient performance, and our continued commitment to delivering affordable, high-quality medicines to patients worldwide.”

Lupin Limited Dow Jones Best-in-Class Indices DJBIC World Index DJBIC Emerging Markets Index ESG performance sustainability environmental social governance S&P Global CSA 2025 Corporate Sustainability Assessment ESG leadership sustainable business practices pharmaceutical industry global pharma company responsible growth ethical business practices governance framework financial discipline sustainability recognition global investors ESG rankings emerging markets sustainability healthcare sustainability pharma ESG corporate governance sustainable healthcare affordable medicines high-quality medicines resilient performance ESG investing sustainability journey responsible business pharma leadership API Plus SBU Ramesh Swaminathan

First Published : May 19, 2026 12:00 am